Search results for "Carcinoid tumour"

showing 3 items of 3 documents

Push-and-pull enteroscopy using a single-balloon technique for difficult colonoscopy.

2006

Background and study aims Several factors predict difficult or incomplete colonoscopy with a standard colonoscope, including female gender, low body mass index, extensive diverticulosis, and prior pelvic surgery. Patients and methods A push-and-pull enteroscopy device and a single-balloon technique was used in 14 patients (six men, eight women; mean age 62 +/- 15 years) after failure of ileocolonoscopy or endoscopic therapy using either a standard or a pediatric colonoscope. The original ileocolonoscopy had been performed to investigate colon polyps (n = 6), an obscure inflammatory process in the ileocecal region (n = 6), or iron deficiency anemia with a positive fecal occult stool test (n …

EnteroscopyAdultMalemedicine.medical_specialtyColorectal cancerColonoscopyColonic DiseasesmedicineHumansCarcinoid tumourAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testColonoscopesbusiness.industryStool testGastroenterologyReproducibility of ResultsColonoscopyEquipment DesignMiddle Agedmedicine.diseaseAppendicitisDiverticulosisSurgeryColon polypsFemalebusinessEndoscopy
researchProduct

Performance of Finnish biobanks in nationwide pulmonary carcinoid tumour research

2019

Finnish hospital-integrated biobanks administer millions of formalin-fixed paraffin-embedded tissue samples collected within the clinical diagnostics. According to the Finnish Biobank Act, these samples can be coupled with patients’ clinical follow-up data and the data retrieved from national health registries. We collected a nationwide pulmonary carcinoid tumour series from Finnish biobanks to study prognostic factors as well as to explore how the number of tumours found in the Finnish biobanks corresponds to the number of tumours registered by the Finnish Cancer Registry (FCR). Finnish biobanks identified 88% of the tumours registered by the FCR and were able to deliver 63%. The main reas…

Male0301 basic medicineLung NeoplasmsProliferation indexbiopankitDiseaseNeuroendocrine tumorskeuhkosyöpäPulmonary carcinoidTumour tissue0302 clinical medicineRARERegistriesINDEXFinlandBiological Specimen BanksOUTCOMESrare cancerSURGICAL RESECTIONGeneral MedicineMiddle AgedPrognosisBiobank3. Good healthbiobank030220 oncology & carcinogenesisMediastinal lymph nodeSURVIVALOriginal ArticleFemaleBURDENpulmonary carcinoidAdultmedicine.medical_specialty3122 CancersCarcinoid TumorPathology and Forensic Medicine03 medical and health sciencesInternal medicinemedicineQUALITYHumansharvinaiset tauditMolecular BiologyBiobankbusiness.industryRare cancerennusteetCell Biologymedicine.diseaseCarcinoma NeuroendocrineCancer registryPulmonary carcinoid tumour030104 developmental biologyEXPERIENCEprognosis3111 BiomedicinebusinessNEUROENDOCRINE TUMORSVirchows Archiv
researchProduct

European disparities in malignant digestive endocrine tumours survival.

2009

The aim of this study was to report on malignant digestive endocrine tumours (MDET) prognosis in several European countries. We analysed survival data from 19 cancer registries in 12 European countries on 3,715 MDET diagnosed between 1985 and 1994. The overall 5-year survival rate was 47.5%. It was 58.1% for differentiated MDET and 8.1% for small-cell MDET (p < 0.001), 55.9% for patients under 65 and 37.0% for older patients. Survival rates for small intestinal and colorectal were higher than for the other sites. The 5-year relative survival rates were 60.3% in Northern Europe, 53.6% in Western Continental Europe, 42.5% in the UK, 37.6% in Eastern Europe (p < 0.001). Among well-differentiat…

MaleCancer Researchmedicine.medical_specialtyPathologyGlucagonomaDigestive System NeoplasmsGastroenterologydigestive endocrine tumours survivalInternal medicineEndocrine Gland NeoplasmsmedicineHumansCarcinoid tumourRegistriesSurvival rateAgedNeoplasm StagingGastrinomaRelative survivalbusiness.industryAbsolute risk reductionCancerMiddle Agedmedicine.diseasePrognosisCancer registryEuropeSurvival RateOncologyFemalebusinessInternational journal of cancer
researchProduct